Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 15/20 | 0.51 |
| ▸ | SMARCA4 | P51532 | 15/20 | 0.51 |
| ▸ | PBRM1 | Q86U86 | 16/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30797014 | 1.00 | SMARCA2 (0.51) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL30796771 | 0.88 | SMN1; SMN2 (0.41) | HDAC1 | |
| SCHEMBL30797119 | 0.88 | SMN1; SMN2 (0.41) | HDAC1 | |
| SCHEMBL29704240 | 0.86 | PBRM1 (0.71) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL29704246 | 0.86 | PBRM1 (0.71) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL23301459 | 0.84 | SMARCA2 (0.53) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL30797027 | 0.84 | SMARCA2 (0.53) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL29943157 | 0.84 | SMARCA2 (0.53) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL22776672 | 0.84 | SMARCA2 (0.45) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL23303238 | 0.83 | SMARCA2 (0.51) | SMARCA2SMARCA4PBRM1BRD4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023244764-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |